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Abstract
Antithrombotic therapy is the cornerstone of the treatment of acute coronary syndromes, but
there is now evidence which indicates that by blocking inflammation, thrombosis and thus, acute
coronary events, could be lowered. The concept of athero-inflammation emerges as the meeting
point of different morbidities; dyslipemia, diabetes, hypertension, obesity, immunity, infection,
hyperhomocyteinemia, smoking, etc. usual named as risk factors. Thus, beside specific drugs,
earliest treatment, in the stage of inflammation, using anti-inflammatory drugs, should be
considered since in patients with increased risk of acute coronary process are likely to have many
point of origen throughout the coronary arteries. There are a body of evidences for supporting the
potential of anti-inflammatory therapy to the prevention of inflammation and atherosclerosis.
COX-2 inhibition may decrease endothelial inflammation reducing monocytes infiltration
improving vascular cells function, plaque stability and probably resulting in a decrease of coronary
atherothrombotic events.
Trials including large numbers of patients in prospective double-blind randomized studies
worthwhile to confirm the efficacy of NSAID, mainly, COX-2 inhibitors, together with aspirin in
the prevention of coronary events in patients with acute coronary disease.
Introduction
Antithrombotic therapy is currently the cornerstone of the
treatment of acute coronary syndromes [1]. Findings indi-
cate the importance of inflammation in atherothrombosis
and support therapeutic use of anti-inflammatory treat-
ment [2]. Thrombosis, as consequence of activation of
platelets, thrombin generation through the coagulation
cascade and inhibition of the fibrinolytic system, follows
inflammation and end in an acute coronary syndrome
(Figure). There is now evidence that blocking inflamma-
tion could lower thrombosis and thus acute coronary
events.
Aspirin
Combining aspirin and heparin is the antithrombotic
treatment of choice in patients with unstable angina, but
therapy starts when the clot is already constituted and the
coronary lumen totally or partially occluded. Further-
more, thrombus formation results from several different
pro-aggregating platelet stimuli and through more than
one mechanism of thrombin generation. Aspirin acts by
irreversible acetylation of cyclooxygenase-1 (COX-1),
reducing the production of pro-aggregating thromboxane
A2 in platelets and formation of the platelet aggregation
inhibitor prostacyclin in the vascular wall. Acetylsalicylic
acid is a relatively weak antiplatelet agent and the conjoint
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activities of two agonists can overcome the inhibitory
effect of aspirin on platelet aggregation [3]. The main
question is whether, for the prevention of cardiovascular
events, other effects of aspirin could be as important or
more important than its inhibition of platelet
aggregation.
There is considerable evidence for multi-factorial effects of
aspirin. In animal models, aspirin significantly decreased
levels of inflammatory factors (soluble intercellular mole-
cule-1, monocyte chemoattractant protein-1, tumor
necrosis factor-α, interleukins), inhibited cell prolifera-
tion [4,5] and diminished in vitro thrombin generation in
a pure intrinsic clotting assay of platelet rich plasma acti-
vated by sodium arachidonate [6]. Kharbanda et al. [7]
produced experimental inflammation in volunteers
through the administration of salmonella vaccine. Pre-
treatment with 1.2 g of aspirin preserved endothelial func-
tion and diminished the increase of the inflammatory
marker IL-1 receptor antagonist, but had no effect on IL-6.
Chlamydia pneumoniae is known to infect and replicate in
cell types found within the atherosclerotic lesion, includ-
ing endothelial cells, smooth muscle cells, and macro-
phages [8,9]. Infection of these cells results in increased
expression of pro-inflammatory cytokines and adhesion
molecules. The cardio-protective effect of aspirin at low
concentration may be due, at least in part, to inhibition of
growth of C pneumoniae due to the inhibition of C
pneumoniae-induced NF-κB activation [10].
There is evidence of an inflammatory component in the pathogenesis of atheroma rupture in acute coronary events Figure 1
There is evidence of an inflammatory component in the pathogenesis of atheroma rupture in acute coronary events. Inflamma-
tion comes about in response to endothelial injury or dysfunction or hemo-reological modifications and precede thrombus 
formation.
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Aspirin therapy appears to be particularly effective among
individuals with high CRP levels [11]. This was detected in
a subset of healthy men in the Physicians Health study. In
patients within the highest quartile of C-reactive protein
elevation the benefit of aspirin (325 mg/day every other
day) was most significant compared with the lowest quar-
tile. In patients with coronary artery disease aspirin also
seems to reduce C-reactive protein levels [12].
Therefore, aspirin may prevent coronary thrombotic dis-
ease through systemic effects independent of its antiplate-
let action. These findings reflect a potential antibacterial
effect as well as inhibition of the clotting mechanism,
plaque growth, and inflammation. It remains to know
whether patients benefit derive from COX-2 inhibition
capacity of aspirin. Thus the range of influences of aspirin
could reflect its anti-inflammatory effect rather than its
anti-platelet properties [13].
The use of aspirin has increased since it was shown to
reduce the risk of myocardial infarction and stroke
[14,15], although meta-analysis suggested that the data
were inconclusive [16]. Although aspirin is a widely used
weak platelet aggregation inhibitor there are discrepancies
on its efficacy in preventing coronary events [16–19].
Thienopyridines
The thienopyridines ticlopidine and clopidogrel are
inhibitors of platelet function in vivo and frequently used
as an antithrombotic agent in coronary disease. Clopidog-
rel is an inactive thienopyridine prodrug that requires in
vivo conversion in the liver to an active metabolite that
exerts its antiplatelet effect by forming an inactivating
disulfide bond with the platelet P2Yac (P2Y12) adenosine
diphosphate (ADP) receptor [20].
Clopidogrel may have some anti-inflammatory effects.
Clopidogrel decreased serum level of soluble intercellular
adhesión molecule-1 (ICAM-1) and diminished chemok-
inesis of monocytes [21]. Klinkhardt et al [22,23] showed
that platelet-leukocyte aggregate formation enhanced in
atherosclerotic vascular disease was reduced by effect of
clopidogrel. This effect appeared to be increased by com-
bining ticlopidine and aspirin [24].
Opposite to the potential anti-inflammatory activity of
clopidogrel, a patient who developed a systemic inflam-
matory response syndrome after receiving clopidogrel
before coronary angiography and stent implantation was
published. The reaction was resolved after withdrawal of
the drug.[25].
Other non-steroidal anti-inflammatory drugs (NSAIDs)
Other NSAIDs have been investigated for beneficial effects
on the risk of cardiovascular thrombosis. Flurbiprofen
was evaluated in a double-blind, pacebo-controlled, mul-
ticentre study for preventing reinfarction or reocclusion
after thrombolysis or coronary angioplasty in patients
with acute myocardial infarction [26]. Indobufen, a
reversible cyclo-oxygenase inhibitor, was compared with a
combination of aspirin and dipyridamole in patients who
had undergone coronary artery bypass surgery in two
prospective, randomized, double-blind clinical trials, per-
formed in the United Kindom and Italy [27]. In the Bro-
chier's study [26], 233 patients were treated with
flurbiprofen 50 mg twice daily and 228 patients with pla-
cebo. The reinfarction rate during the 6-month follow-up
was 3% in the group treated with the active drug and
10.5% in the placebo group (P < 0.001). These results
indicated that flurbiprofen reduced the rate of myocardial
infarction compared with placebo and that its efficacy was
similar to aspirin+ dipyridamole for preventing graft
occlusion after coronary artery bypass surgery.
The effect of NSAIDs after acute myocardial infarction was
also investigated retrospectively in the DAVIT study [28]
where 88 patients received regular randomized non-ster-
oidal anti-inflammatory drugs treatment. It was con-
cluded that treatment was safe with regard to mortality
and re-infarction. In the multivariate analysis a non-sig-
nificant beneficial trend in favor of NSAIDs was observed.
The lack of significance was attributed to the small sample
size [28].
The effects of NSAIDs including naproxen on the risk of
serious coronary heart disease was studied observationally
by Ray et al [29]. The study included 181441 users of
NSAIDs and equal numbers of non-users. The endpoint
was hospital admission for acute myocardial infarction or
death from coronary heart disease. Uninterrupted use for
more than 60 days conferred no protection on the NAN-
SAID users. The authors suggested that in the absence of
any protective effect of naproxen or other NANSAIDs on
risk of coronary heart disease, these drugs should not be
used for cardioprotection [29].
Rahme et al. [30] compared the effects of naproxen vs
other NSAIDs on the prevention of acute myocardial inf-
arction in patients aged 65 years or over. In 4163 cases
and 14160 controls they found that compared with other
NSAIDs, concurrent exposure to naproxen had a protec-
tive effect against acute myocardial infarction [30].
From the few published trials, therefore, the effect of
NSAIDs in the prevention of acute myocardial infarction
is controversial. Although complex and apparently con-
flicting data have been obtained, and some results con-
cerning the use of aspirin have been challenged [16], its
effect is more widely accepted than other NSAIDs. ItsThrombosis Journal 2003, 1 http://www.thrombosisjournal.com/content/1/1/2
Page 4 of 6
(page number not for citation purposes)
inhibitory effect on COX-1 is probably most important
for the prevention of thrombotic coronary disease.
Selective Cox-2 Inhibitors
Cyclooxygenases (COX-1, COX-2) are involved in throm-
boxane and prostacyclin formation and in the inflamma-
tory process. COX-1 synthesizes prostaglandins from
arachidonic acid and the two most important active final
products, thromboxane A2  and prostacyclin, regulate
platelet function. COX-2 is inducible, for example by pro-
inflammatory cytokines and growth factors, implying a
role for COX-2 in both inflammation and the control of
cell growth [31]. COX-2 promotes early atherosclerotic
lesion formation in LDL receptor-deficient mice in vivo
[32].
The toxicity of NSAIDs is related to COX-1 inhibition. In
the stomach COX-1 inhibition diminishes the synthesis
of protective prostaglandins. The new drugs with more
selective COX-2 inhibition activity reduce inflammation
without removing the protective prostaglandins in the
stomach, so they cause fewer gastrointestinal complica-
tions than traditional NSAIDs [33]. Aspirin acts by irre-
versible acetylation of a serine residue at position 529 in
COX-1 reducing thromboxane A2 generation in platelets
and prostacyclin formation in the vascular wall. COX-2
inhibitors do not affect platelet COX-1 activity but block
prostacyclin formation in endothelial cells [34,35].
The data suggest that in vivo, prostacyclin modulates
thromboxane A2-mediated interactions between platelets
and the vessel wall. Thus an imbalance in the pro/ anti-
thrombotic forces could be produced. The result is an
increase of platelet activation, potentially shifting the hae-
mostatic balance towards a prothrombotic state.
A selective inhibitor of COX-2, celecoxib, significantly
improved endothelium-dependent vasodilation; also, C-
reactive protein was significantly lower after celecoxib
than after placebo. Both effects could be relevant to
chronic inflammation [36].
Matrix metalloproteinases degrade most components of
the extracellular matrix and basement membrane and
may contribute to atherosclerotic arterial wall remodeling
and to plaque rupture. Co-expression of COX-2 and met-
alloproteinase by macrophages in atherosclerotic plaque
has been reported [37]. COX-2 is involved in the inflam-
matory response via the generation of prostanoids that in
turn are involved in the production of matrix metallopro-
teinases [38].
Experimental results indicate a marked inflammatory
response at stent implantation sites. Inflammation is
involved in neointimal proliferation and restenosis. A
high pre-procedural of plasma CRP and its persistent ele-
vation has predictive value for risk of restenosis [39].
Thus, a body of evidence supports the potential of anti-
inflammatory therapy for preventing inflammation and
atherosclerosis. COX-2 inhibition may decrease endothe-
lial inflammation, reducing monocyte infiltration,
improving vascular cell function and plaque stability, and
probably resulting in a decrease of coronary atherothrom-
botic events [40]. Concern that COX-2 inhibitors might
predispose to cardiovascular thrombotic events came to
center stage with publication of the VIGOR Study [33],
where the COX-2 inhibitor rofecoxib was compared with
the nonsteroidal antiinflamatory naproxen in patients
with rheumatoid arthritis. The study showed a 5-fold
increase in cardiovascular events associated with
rofecoxib therapy. Nevertheless, there is no definitive evi-
dence that COX-2 inhibitors increase (or decrease) the
risk of myocardial infarction, and the VIGOR study results
and similar findings have been challenged [41–45].
Indeed, the results are readily explicable in terms of a ben-
eficial effect of naproxen rather than a detrimental effect
of COX-2 inhibitors [45]. Very recently, Mamdani et al.
[46] conducted a retrospective study in subjects aged 66
years or older in whom treatment was initiated with
celecoxib, or rofecoxib, or naproxen, or non-naproxen
non-selective NSAIDs. Observations were compared with
a randomly selected control cohort not exposed to
NSAIDs. The results indicated that COX-2 inhibitors did
not increase the risk of acute myocardial infarction, nor
did naproxen reduce the risk in the short term.
To date, different studies have given controversial results.
Depression of vascular prostaglandin I2 production in the
absence of concomitant platelet inhibition [41], and con-
cern about cardiovascular safety of COX-2 inhibitors [42],
have enhanced awareness of the need for adjuvant
antiplatelet therapy, mainly aspirin, in appropriate
patients who are receiving COX-2 inhibitors [45], mainly
when there is a comorbidity such as chronic vascular dis-
ease, hypertension, diabetes or dyslipemia. When the
COX-2 inhibitor celecoxib was used together with aspirin
there was no additional decrease in prostacyclin forma-
tion, and thromboxane A2 production was not increased
[36]. There have been few studies evaluating the use of
NSAIDs with mainly COX-2 inhibitory effects in the treat-
ment of acute coronary syndrome.
Corticosteroids
In the MUNA trial [47], patients with a diagnosis of unsta-
ble angina were randomized to a 48-h course of methyl-
prednisolone (n = 81) or placebo (n = 85). Forty-eight
hours after randomization, mean C-reactive protein levels
decreased by 2.6 mg. l-1 in the methylprednisolone group,
but increased by 1.6 mg. l-1 in the placebo group (P =Thrombosis Journal 2003, 1 http://www.thrombosisjournal.com/content/1/1/2
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0.03). Attainment of the primary end-point (in-hospital
recurrence of angina, silent ischaemia on Holter record-
ing, emergency coronary revascularization, readmission
with unstable angina, or myocardial infarction or death)
was not significantly different in the two groups: it
occurred in 44% of the methylprednisolone patients and
33% of the placebo patients (P = 0.12) [47].
In a double-blind, randomized, placebo control study,
Versaci et al [48], employed oral prednisolone in 41
patients who had undergone stent implantation. The con-
trol group comprised forty three patients under placebo.
All patients received combined aspirin and ticlopidine for
3 days before implantation. Prednisolone therapy was
sustained for 45 days, starting with 1 mg/kg for the first 10
days. Only patients with a CRP level >0.5 mg/dl 72 h after
the procedure were included in the study. Primary end-
points were death, myocardial infarction, or recurrence of
symptoms requiring additional revascularization. In this
trial, prednisolone was associated with a 28% absolute
reduction of clinical events (p = 0.0063) at 12-months fol-
low-up and with a 26% absolute reduction of restenosis
rate (p = 0.001) at 6-months follow-up [48]. Results of
both studies are controversial but the designs were dissim-
ilar in several ways: patients with unstable angina were
included in the MUNA trial and those after coronary
artery stent implantation in the IMPRESS study; pred-
nisolone doses were different; the treatments were 48 h
and 45 days respectively; the follow up was 30-day in the
MUNA study and 12-month in the IMPRESS study.
NSAIDs with mainly COX-2 inhibitory effects
There have been few studies evaluating the use of NSAIDs
with mainly COX-2 inhibitory effects in the treatment of
acute coronary syndrome.
A pilot study was performed by Altman et al. [49] employ-
ing meloxicam, a preferential COX-2 inhibitor. In 120
patients with acute coronary syndrome without ST-seg-
ment elevation, sixty patients were treated with meloxi-
cam, 15 mg daily for 30 days. All patients received
standard therapy with heparin and aspirin. The primary
endpoint was the composite of recurrent angina, MI, or
death during CCU stay and after 90 days of follow-up. A
secondary endpoint was MI, death, and all revasculariza-
tion procedures (percutaneous transluminal coronary
angioplasty or coronary artery graft surgery). Events at cor-
onary care unit as well as after 90 days of follow up were
less frequent in the meloxican-treated group than in the
placebo group. At 90 days of follow-up, the relative risk
reduction was 55.1% (p = 0.015) and the absolute risk
reduction was 26.6% for primary end points. The corre-
sponding figures for secondary end points were 60.1 % (p
= 0.015) and 20.0% respectively.
Supported by the concept of athero-inflammation and by
the result of trials where anti-inflammatory drugs were
used, beside specific drugs use of anti-inflammatory drugs
in the early stages of inflammation should be considered,
since patients with increased risk of acute coronary proc-
ess are likely to have many points of origin throughout the
coronary arteries [50,51]. The concept that coronary dis-
ease is a systemic disease of the entire coronary tree must
be taken into account when treatment of patients with
acute coronary disease is considered [52]. Systemic medi-
cal therapy has proved superior to coronary angioplasty in
such chronic high risk patients [53].
Conclusions
If the emerging evidence for the central role of inflamma-
tion in the development of acute coronary disease is
accepted, additional trials including large numbers of
patients in prospective double-bind randomized studies
are worthwhile to confirm the efficacy of NSAID (mainly,
COX-2 inhibitors together with aspirin) in the prevention
of coronary events in acute coronary disease patients.
Surely the medical community will welcome new data for
resolving the complex and apparently conflicting data
concerning the prevention of thrombotic coronary events
by the use of selective COX-2 inhibitor drugs. This can
only be answered through large well-designed clinical
trial.
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